Reyvow FDA Approval History
Last updated by Judith Stewart, BPharm on July 27, 2020.
Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
- Reyvow is the first in the new class of drugs called ditans (serotonin (5-HT)1F receptor agonists) which have potentially fewer vasoconstriction side effects compared to triptans.
- Reyvow tablets are taken orally as needed. No more than one dose should be taken in 24 hours.
- Reyvow causes central nervous system (CNS) depression and the results of clinical studies reported high rates of CNS related adverse reactions including dizziness and sedation. Patients taking Reyvow must be warned that the drug may cause significant driving impairment and they are advised not to drive or operate machinery for at least 8 hours after taking a dose. Patients who cannot follow this advice should not take Reyvow.
- Common side effects include dizziness, fatigue, paresthesia ('pins and needles'), and sedation.
- Lasmiditan will be scheduled under the Controlled Substances Act (DEA decision pending) due to its potential for abuse and dependence.
Development Timeline for Reyvow
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.